By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous coagulation modifiers > Rebinyn > Rebinyn Dosage
Miscellaneous coagulation modifiers
https://themeditary.com/dosage-information/rebinyn-dosage-3863.html

Rebinyn Dosage

Drug Detail:Rebinyn (Coagulation factor ix [ koe-ag-yoo-lay-shun-fak-tor-nine ])

Generic Name: COAGULATION FACTOR IX RECOMBINANT HUMAN 125[iU] in 1mL;

Dosage Form: kit

Drug Class: Miscellaneous coagulation modifiers

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

For intravenous infusion after reconstitution only.

Dosing Guidelines

•
Dose and duration of treatment depend on the location and extent of bleeding, and the patient’s clinical condition.
•
If monitoring of Factor IX activity is performed, use a chromogenic assay or selected one-stage clotting assay validated for use with REBINYN [see Warnings and Precautions (5.5)].
•
Each carton and vial label for REBINYN states the actual Factor IX potency in IU.

On-demand Treatment and Control of Bleeding Episodes

REBINYN dosing for on-demand treatment and control of bleeding episodes is provided in Table 1.

Table 1: Dosing for On-demand Treatment and Control of Bleeding Episodes

Type of bleeding

Recommended dose

IU/kg body weight

Additional information

Minor and moderate

For example: Uncomplicated joint bleeds, minor muscular bleeds, mucosal or subcutaneous bleeds

40

A single dose should be sufficient for minor and moderate bleeds. Additional doses of 40 IU/kg can be given.

Major

For example: Intracranial, retroperitoneal, iliopsoas and neck bleeds, muscle bleeds with compartment syndrome and bleeds associated with a significant decrease in the hemoglobin level

80

Additional doses of 40 IU/kg can be given.

Perioperative Management

REBINYN dosing for perioperative management is provided in Table 2.

Table 2: Dosing for Perioperative Management

Type of surgical procedure

Recommended dose

IU/kg body weight

Additional Information

Minor

For example: Implanting pumps in subcutaneous tissue, skin biopsies or simple dental procedures

40

A single pre-operative dose should be sufficient. Additional doses can be given if needed.

Major

For example: Body cavity is entered, mesenchymal barrier is crossed, fascial plane is opened, organ is removed, normal anatomy is operatively altered

80

Pre-operative dose

40

As clinically needed for the perioperative management of bleeding, repeated doses of 40 IU/kg (in 1-3 day intervals) within the first week after major surgery may be administered.*

Due to the long half-life of REBINYN, the frequency of dosing in the post-surgical setting may be extended to once weekly after the first week until bleeding stops and healing is achieved.

*See 12.3 Pharmacokinetics, Table 8

​Routine Prophylaxis

​For prophylaxis use, the recommended dose is 40 IU/kg body weight once weekly.

​Adjust dosing regimen based on individual patient’s bleeding pattern, and physical activity.

Reconstitution

•
Always wash hands and ensure that the area is clean before performing the reconstitution procedures.
•
Use aseptic technique during the reconstitution procedures.
•
If the patient uses more than one vial of REBINYN per infusion, reconstitute each vial according to the following instructions.

Overview of REBINYN Package

Overview of REBINYN Package

The instructions below serve as a general guideline for reconstitution of REBINYN. For full instructions, refer to the FDA-approved patient information and Instructions for Use.

Reconstitution

1.
Bring the REBINYN vial and the pre-filled diluent syringe to room temperature.
Fig. A
2.
Remove the plastic cap from the REBINYN vial.
Fig. B
3.
Wipe the rubber stopper on the vial with a sterile alcohol swab and allow it to dry prior to use.
4.
Remove the protective paper from the vial adapter. Do not remove the vial adapter from the protective cap.
Fig. C
5.
Place the vial on a flat and solid surface. While holding the protective cap, place the vial adapter over the REBINYN vial and press down firmly on the protective cap until the vial adapter spike penetrates the rubber stopper.
Fig. D
6.
Remove the protective cap from the vial adapter.
Fig. E
7.
Grasp the plunger rod as shown in the diagram. Attach the plunger rod to the syringe by holding the plunger rod by the wide top end. Turn the plunger rod clockwise into the rubber plunger inside the pre-filled diluent syringe until resistance is felt.
Fig. F
8.
Break off the syringe cap from the pre-filled diluent syringe by snapping the perforation of the cap.
FIg. G
9.
Connect the pre-filled diluent syringe to the vial adapter by turning it clockwise until it is secured.
Fig. H
10.
Push the plunger rod to slowly inject all the diluent into the vial.
Fig. I
11.
Without removing the syringe, gently swirl the REBINYN vial until all of the powder is dissolved.
Fig. J
12.
Administer the REBINYN solution immediately [see Administration (2.3)]. If not used immediately after reconstitution, store the solution in the vial with the vial adapter and the syringe attached, at room temperature ≤ 86°F (30°C). Do not store for longer than 4 hours.

Administration

For intravenous infusion only.

•
Accidental needle stick with a needle contaminated with blood can transmit infectious viruses including HIV (AIDS) and hepatitis. If a needle stick occurs, obtain immediate medical attention. Place needles in a sharps container after single use.
•
Inspect the reconstituted REBINYN solution visually prior to administration [see Description (11)]. The solution should be clear and have no particles. Do not use if particulate matter or discoloration is observed.
•
Do not administer REBINYN in the same tubing or container with other medicinal products.
1.
Invert the REBINYN vial and slowly draw the solution into the syringe.
Fig. K
2.
Detach the syringe from the vial adapter by turning the syringe counterclockwise.
3.
Attach the syringe to the luer end of an infusion needle set.
4.
Infuse the reconstituted REBINYN intravenously slowly over 1 to 4 minutes.
5.
After infusion, safely dispose of the syringe with the infusion set, the vial with the vial adapter, any unused REBINYN, and other waste materials.

Caution: The pre-filled diluent syringe is made of glass with an internal tip diameter of 0.037 inches, and is compatible with a standard Luer-lock connector.

Some needleless connectors for intravenous catheters are incompatible with the glass diluent syringes (for example, certain connectors with an internal spike, such as Clave® /MicroClave®, InVision-Plus®, InVision-Plus CS®, Invision-Plus Junior®, Bionector®), and their use can damage the connector and affect administration. To administer REBINYN through incompatible needleless connectors, withdraw the reconstituted product into a standard 10 mL sterile Luer-lock plastic syringe.

If you encounter any problems with attaching the pre-filled histidine-diluent syringe to any Luer‐lock compatible device, please contact Novo Nordisk at (844) 303-4448.

Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by